Menopausal symptoms and quality of life of hormone receptor positive breast cancer patients at different endocrine therapy time
10.3760/cma.j.issn.0253-3766.2020.01.008
- VernacularTitle: 激素受体阳性乳腺癌患者在不同内分泌治疗用药时间的类更年期症状及生命质量
- Author:
Xu LI
1
;
Hao WANG
2
;
Hongping XU
1
;
Sha DIAO
1
;
Yangwen ZHOU
1
;
Fang YI
1
;
Hui LI
2
;
Jiachang LI
1
;
Yu HAO
1
;
Jiayuan LI
1
Author Information
1. West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu 6l0041, China
2. Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu 6l0041, China
- Publication Type:Clinical Trail
- Keywords:
Breast neoplasms;
Endocrine therapy;
Therapy time;
Menopausal symptoms;
Quality of life
- From:
Chinese Journal of Oncology
2020;42(1):55-60
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the menopausal symptoms and quality of life of hormone receptor positive (HR+ ) breast cancer patients at different endocrine therapy time.
Methods:The HR+ breast cancer patients who were pathologically confirmed from 2011 to 2017 in the Sichuan Cancer Hospital were divided into three groups according to endocrine therapy time (<12 months, 12~36 months, >36 months) and analyzed by a cross-sectional study. The Menopausal symptoms and quality of life of these patients were measured using the modified Kupperman scale and the functional assessment of cancer therapy-breast cancer (FACT-B) scale. The differences of menopausal symptoms among different time groups and drug groups were analyzed by Chi-square test. The differences of quality of life and the effects of menopausal symptoms on quality of life were tested by covariance and multiple linear regression analyses.
Results:The average score of menopausal symptom of 167 patients was 14.5±7.6 and the prevalence rate was 87.4% (146/167). Among all of the menopausal symptoms, the prevalence rate of insomnia was the highest (73.7%, 123/167). Besides insomnia and excitement, hot flashes was more prevalent in selective estrogen receptor modulator (SERM) users (64.8%, 79/122) , while osteoarthritis was more prevalent in aromatase inhibitor (AI) users (62.2%, 28/45). The total score of FACT-B of Patients was 104.5±15.5, and the compliance rate was up to 89.8% (150/167). However, the condition of each dimension was different, the compliance rates of social/ family and functional dimension were lowest, which were 73.0% (122/167) and 50.9% (85/167), respectively. The menopausal symptoms of patients at different time groups were 15.0±1.3, 14.0±6.9, 14.5±7.4, respectively, and the total score of FACT-B of patients at different time groups were 102.7±17.8, 105.0±12.9, 105.6±16.7, respectively, without significant differences (both P>0.05). Multiple linear regression analysis showed that menopausal symptoms impaired the quality of life of SERM users during the endocrine therapeutic period. The standardized regression coefficients of three time groups were -0.67, -0.30, -0.50, respectively, with the lowest effect on 12~36 months group.
Conclusion:HR+ breast cancer patients will have a poor function recovery and social/ family return, who need more attention. Menopausal symptoms are common problems during endocrine therapy, and active measures should be taken to improve patients′ quality of life.
